Background. Overlapping clinical, endoscopic, radiographic and histological features, coupled with poor microbiological yield, make differentiating Crohn's disease (CD) from intestinal tuberculosis (ITB) challenging. Granulomas are present in both diseases; in CD they predict the need for immunosuppressive therapy that requires ITB to be excluded before initiation. Objectives. To compare granuloma-positive CD and ITB, to identify factors that may aid in diagnosis.
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Crohn's disease (CD) is a chronic inflammatory disorder that can affect any part of the gastrointestinal tract (GIT), notably the terminal ileum and caecum. The major differential diagnosis of CD in our setting in Cape Town, South Africa (SA), is intestinal tuberculosis (ITB). Both disorders share overlapping clinical, endoscopic, radiographic and histological features, notably the presence of tissue granulomas. Coupled with a poor microbiological yield in ITB, this makes differentiating these diseases challenging. Traditional diagnostic modalities such as acid-fast bacilli (AFB), Mycobacterium tuberculosis (MTB) culture, tuberculin skin testing, interferongamma release assays and chest radiographs are often negative in ITB. [1] In addition, polymerase chain reaction (PCR) testing of the GIT for MTB is not validated in our setting and is not currently recommended or approved. Given the very high incidence and prevalence of MTB infection in SA, a diagnosis of CD is only made once ITB has been excluded. This often requires an empirical trial of anti-tuberculosis (anti-TB) therapy. [1, 2] Misdiagnosis leads to delays in initiating effective therapy for CD, while the use of potent immunomodulators (IMMs) and biologicals in the setting of ITB can have fatal consequences. It is therefore important to make an accurate diagnosis at the earliest possible stage.
The differentiation of ITB from CD is particularly problematic in patients with non-caseating granulomas, as these suggest a very real possibility of ITB. [3] To date, no study has been done in this particular subgroup to analyse factors that could aid in this diagnostic dilemma.
Objective
To compare patients with granuloma-positive CD and ITB, to identify variables that could aid in differentiating between the two conditions.
Methods
The research protocol was approved by the Ethics Committee of the University of Cape Town (ref. no.833/2014). A retrospective cohort study (2005 -2015) was conducted evaluating adult patients with granuloma-positive CD or ITB. Subjects were identified from a pathology database and information was extracted from patient folders and laboratory and radiology records.
The following data were collected at presentation: demographics, clinical, biochemical, histological and radiographic variables, and HIV status (Tables 1 -4) .
The diagnosis of CD was made on the basis of a combination of clinical, radiological, endoscopic and histological features as per the European Crohn's and Colitis Organisation consensus statement. [4] ITB was diagnosed if any of the following were present: AFB positivity on tissue biopsy, positive culture for MTB, and full response after completion of anti-TB treatment.
Statistical analysis
The association between all baseline risk factors and the diagnosis of CD and ITB was assessed by univariate analysis. Normally distributed continuous variables are expressed as means (standard deviations (SDs)). Continuous variables that were not normally distributed are expressed as medians and interquartile ranges (IQRs). Categorical variables were compared using the χ 2 
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Results
Sixty-eight patients with ITB and 48 with CD with granulomas were identified. Of those with ITB, 42 (61.8%) had AFB present on Ziehl-Neelsen staining and 36 (52.9%) were culture-positive for MTB. At presentation (Table 1) , patients with ITB were younger than those with CD (p=0.03), and more likely to be male (p=0.03) and of black ethnicity (p<0.0001). Isolated colonic involvement was significantly more common in ITB than in CD (p=0.04). There were no significant differences in smoking status, symptom duration or perianal disease.
Clinical variables associated with a diagnosis of ITB (Table 2 ) were a history of night sweats (p=0.01) and tachycardia (p<0.0001) at presentation. Patients with CD were significantly more likely to have extraintestinal manifestations (EIMs) than those with ITB (p<0.0001). The commonest EIM in CD was iron deficiency anaemia (IDA). The only other two EIMs of note were erythema nodosum (n=4 cases) and uveitis (n=2), all in patients with CD. Other symptoms such as diarrhoea, abdominal pain and weight loss were not significant. Similarly, fever, the presence of an abdominal mass on palpation and ascites on clinical examination were not predictive.
Thirty-three percent of patients with ITB had a chest radiograph with features of active tuberculosis (TB); this was predictive of concurrent ITB (p<0.0001). In contrast, radiographic features suggesting past TB were not. Overall, only 62.1% of the cohort had undergone cross-sectional imaging at presentation (Table 4) . Of the radiographic abnormalities reported, only lymph nodes >1 cm in size and ascites were predictive of ITB. There were no significant differences with regard to the presence of central node attenuation, splenic abscesses, inflammatory masses or intraabdominal collections.
Thirty-five patients with ITB (51.5%) were HIV-positive, as opposed to a single patient in the CD group. HIV positivity was significantly associated with a diagnosis of ITB (p<0.0001). The mean (SD) CD4+ count in the HIV-positive patients was 269 (250) cells/µL.
ITB was also associated with lower serum albumin (p<0.0001) and haemoglobin (p<0.0001) values at presentation than CD, as well 
Discussion
Differentiating ITB from CD is notoriously challenging, as they share numerous clinical, endoscopic and radiographic features. Both diseases can affect the GIT at any point from the mouth to the anus, with a predilection for the ileocaecal region. Both may present with perianal disease, intestinal strictures or fistulas, and in addition they share many EIMs. Distinguishing ITB from CD in SA is further complicated by very high rates of MTB infection. Although most cases are pulmonary, extrapulmonary TB can occur, and the GIT is commonly affected. [5, 6] Treating undiagnosed ITB with potent immunosuppressive CD medications can have potentially fatal consequences, particularly the risk of dissemination. If the diagnosis is unclear, common practice is therefore to give a trial of anti-TB therapy and assess the clinical response. [2] This approach is far from ideal, as it delays implementation of appropriate CD medication, which may affect long-term outcomes. CD is a progressive and destructive illness that evolves over time to be complicated by the development of strictures, fistulas or abscesses. Ultimately the majority of patients require surgery. [7] Aggressive medical therapy with IMMs such as azathioprine or methotrexate and biologicals may alter this natural history and improve long-term outcomes. [6] However, to be effective these should be introduced early in the disease course, ideally at diagnosis, before the development of irreversible complications. [6] Several studies have analysed factors early in the course of CD that may predict future outcomes and identify patients at risk of developing complicated CD who would receive greatest benefit RESEARCH from early, aggressive therapy. [6] One such predictor is the presence of tissue granulomas on histological examination. A recent cohort study in the Western Cape Province, SA, showed a two-fold increase in the risk of developing complicated CD in those with this finding at diagnosis. [8] The differentiation of ITB from CD is even more challenging in patients with histological evidence of non-caseating granulomas, as this further heightens the suspicion of ITB. [3] Patients with ITB are significantly more likely to have non-caseating granulomas than those with CD. [1, 3] This was highlighted in a recent meta-analysis of 38 studies differentiating CD from ITB. There were 2 117 cases of CD and 1 589 cases of ITB. The authors used the data to construct a Bayesian model to predict the probability of ITB v. CD. In this analysis, the presence of granulomas was significantly associated with a diagnosis of ITB. [3] Ours is the first study with the objective of identifying factors differentiating ITB from CD in exclusively granuloma-positive patients. Several factors were identified as being valuable in this regard.
On multivariate analysis, the presence of EIMs at diagnosis strongly suggested a diagnosis of CD. This is in concordance with reports from several cohort studies, as well as the formerly mentioned Bayesian model. [3, 9] The commonest EIM in CD was IDA. This finding is not unexpected, as it is the most common systemic complication of CD. [10] The other reported EIMs in the CD patients were erythema nodosum and uveitis.
Several studies have shown that the presence of perianal disease strongly supports a diagnosis of CD. Interestingly, this was not seen in our study. In fact, in our cohort all seven cases of isolated perianal disease were proven to be TB. It is possible that the prevalence of perianal TB is underestimated. A 2009 prospective study from our institution evaluated 96 patients with perianal fistulas. TB was present in 7.3% of cases, suggesting that this is not an uncommon manifestation of TB in our setting. [11] In our study, significantly more patients with ITB than CD had isolated colonic involvement (25.4% v. 11.1%). This is higher than in other series, where only 10% of patients demonstrated this finding. [12] However, the incidence of colonic involvement was increased in immunocompromised patients and in those with HIV. [12] In our cohort, 50.1% of patients with isolated colonic involvement were HIV-infected. This could explain the high incidence of this location.
Other variables supporting a diagnosis of ITB, such as anaemia, hypoalbuminaemia, tachycardia and higher median CRP levels, were no longer significant on multivariate analysis. This probably reflects their association with systemic toxicity and the inflammatory burden seen in HIV-TB co-infection, as they were no longer significant after adjusting for HIV status.
Not unexpectedly HIV, infection was shown to be the strongest risk factor for ITB. It is well recognised that the burden of TB in SA is fuelled by the HIV epidemic, with 7 million South Africans infected with the virus. [13] SA is currently home to 22.5% of all individuals with TB and HIV co-infection across the globe. [13] Interestingly, in our study patients with granulomatous ITB-HIV co-infection had a mean CD4+ count of 269 cells/µL, suggesting that granuloma-positive ITB, which is difficult to differentiate from CD, requires a degree of immune competence. This is supported by data showing that reductions in CD4+ counts in co-infected persons were associated with both poorer granuloma formation and higher bacterial load. [14] 
Study limitations
Given the retrospective nature of this study, there were some missing data points. In addition, there were some disease characteristics that were poorly documented, on which availability of more detail would have enhanced the analysis. These were the number and morphology of granulomas, tuberculin skin testing, the endoscopic mucosal appearance, the number of diseased colonic segments, and features on routine cross-sectional imaging. These would have been useful additional tools, as they have been shown to have good diagnostic accuracy in differentiating CD from ITB. [15] 
Conclusion
Excluding ITB is essential when considering potent immunosuppressive therapies for CD. This study focused on subjects with tissue granulomas at diagnosis, as these predict a severe course of CD. Several clinical and biochemical factors were identified that will aid in making the correct diagnosis, notably HIV infection, which was the strongest risk factor for ITB in this study. Isolated colonic involvement was also associated with ITB, while EIMs predicted a diagnosis of CD. To our knowledge, this is the first study to restrict analysis to granuloma-positive patients, the subgroup in which differentiating CD from ITB is most challenging. These data will aid in ensuring a timely diagnosis and reduce the risk of delayed CD treatment, as well as misdiagnosing ITB.
